Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

It is known that a prostate cancer gene 3 (PCA3) urine assay is superior to serum PSA level or PSA‐related indices for predicting a positive biopsy result in European and US men. This is the first report on PCA3 in a large cohort of Japanese men. The diagnostic value of the PCA3 score in Japanese men was similar to those reported in European and US men. The study concludes that a combination of PSA density and PCA3 score may be useful for selecting patients who could avoid an unnecessary biopsy.

[1]  M. Bornman,et al.  The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting , 2011, BJU international.

[2]  L. Salomon,et al.  Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.

[3]  T. Miki,et al.  Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy , 2011, International journal of urology : official journal of the Japanese Urological Association.

[4]  G. Andriole,et al.  PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. , 2010, The Journal of urology.

[5]  G. Andriole.  PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome , 2009 .

[6]  W. Ellis,et al.  Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. , 2009, European urology.

[7]  Mesut Remzi,et al.  Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.

[8]  P. Troncoso,et al.  PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.

[9]  W. Ellis,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[10]  Amy Blase,et al.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.

[11]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[12]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[13]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[14]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[15]  D. Johnston,et al.  Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. , 1996, The Journal of urology.

[16]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[17]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[18]  L. Marks,et al.  Aptima Pca3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer , 2022 .